Search

Author/Creator Jotte, Robert M

1. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Issue 5 (May 2019)

Authors:
Reck, Martin; Mok, Tony S K; Nishio, Makoto; Jotte, Robert M; Cappuzzo, Federico; Orlandi, Francisco; Stroyakovskiy, Daniil; Nogami, Naoyuki; Rodríguez-Abreu, Delvys; Moro-Sibilot, Denis; Thomas, Christian A; Barlesi, Fabrice; Finley, Gene; Lee, Anthony; Coleman, Shelley; Deng, Yu; Kowanetz, Marc...
Journal:
Lancet
Issue:
Volume 7:Issue 5(2019)
Page Start:
387
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial. Issue 2 (21st February 2022)

Authors:
West, Howard Jack; McCleland, Mark; Cappuzzo, Federico; Reck, Martin; Mok, Tony SK; Jotte, Robert M; Nishio, Makoto; Kim, Eugene; Morris, Stefanie; Zou, Wei; Shames, David; Das Thakur, Meghna; Shankar, Geetha; Socinski, Mark A
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 10:Issue 2(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search